Cost Sharing Program In Part D From Coalition Of Cancer Drug Manufacturers Rebuffed By OIG
Federal watchdog group acknowledges proposed assistance program aligns with comments in a 2005 OIG advisory bulletin on patient assistance programs in Medicare Part D, but maintains the bulletin should not serve as a roadmap for a compliant program in this case.
You may also be interested in...
Cancer Drug Manufacturers Sue HHS OIG Over Denial Of Part D Patient Assistance Program
Complaint against the US government watchdog agency disputes its conclusion that a proposed cost sharing assistance program in Medicare to be funded by a coalition of cancer drug manufacturers would likely violate the federal anti-kickback statute.
Part D Overhaul: The Silver Lining Amid Very Dark Cloud Of US Drug Pricing Bill
Senate version of a potential drug pricing overhaul in the US includes one silver lining for manufacturers: a re-design and update of the Part D drug benefit. Is there any chance of extracting that item for the very dark clouds around it?
Pfizer Switches To Offense In Charity Co-Payment Suit Against HHS
Pfizer is one of 10 pharma companies that have reached settlements with the US Department of Justice over their relationships with co-pay assistance foundations. It now seeks a declaratory judgement that proposed programs for its heart drug tafamidis do not violate the anti-kickback statute.